I am a Research Fellow at PIBBSS (Principles of Intelligent Behaviour in Biological and Social Systems). My current research focuses on the mechanistic interpretability of machine learning, specifically using sparse autoencoders. This work combines my interests in computational modeling and complex systems, now applied to understanding the inner workings of AI.
I was previously a postdoc working at the Cancer Institute at University College London. My main research interests combine biology and computer science, using computational modelling to predict cancer evolution and plan treatment programmes to avert or overcome resistance.
I completed my PhD at the the University of Cambridge, looking at how computational network models could be used to find more effective combination treatments for breast cancer. As a postdoc at the Fisher Lab in the UCL Cancer Institute I am building upon this work in order to predict resistance mechanisms to radiotherapy and to find the most effective patient-specific treatments to overcome them.
I am keen to share my knowledge and expertise with others. As a mentor to postdocs, PhD students, Masters students, and undergraduates, I take pride in helping to guide and inspire the next generation of scientists. If you have any questions about my work, please get in touch with the contact form below.
I am continuing my work on triple-negative breast cancer, non-small cell lung cancer and the automation of network generation using message-passing graph neural networks.
Responsibilities included:
I continued my work on DNA damage repair as part of CRUK RadNet, applying this to breast cancer and lung cancer. I also developed new methods for studying cancer evolution. During the pandemic, my colleagues and I demonstrated how our work on cancer could be applied to infectious disease, to predict drug repurposing for rapid response to the COVID-19 epidemic.
Responsibilities included:
I worked to support Promatix Ltd to accelerate the hunt for oncology therapeutics.
Responsibilities included:
With funding from CRUK RadNet, I worked on modelling the DNA damage response pathway to find radiosensitising drug treatments. I also continued my work on breast cancer, focussing on the triple-negative sub-type (TNBC) as part of a collaboration with the Mark Foundation for Cancer Research and PARTNER clinical trial. In collaboration with Jasmin Fisher I published a review on the opportunities and challenges for executable modelling.
Responsibilities included:
Thanks to generous funding from the Glover Fund, I was able to build upon my work on the evolution of cancer, expanding it to understand how the behaviour of blood cancers is determined by the order in which they acquire mutations, even when their final mutational profile is identical as part of a collaboration with the Hall and Kent labs.
Responsibilities included:
As part of the Wellcome Trust Mathematical Genomics and Medicine PhD programme, studied as part of the University of Cambridge Computational Biology MPhil, while also undertaking rotations in different labs. I then worked in the lab of Jasmin Fisher and the University of Cambridge Department of Biochemistry and Microsoft Research Cambridge. During my PhD, I developed a network model of breast cancer, as well as novel methods to study combination treatment and the evolution of cancers. Using these, in collaboration with the Gerard Evan lab, we were able to identify and validate a novel combination treatment for breast cancer, exploiting the heterogeneity observed in myc driven breast cancers.
Responsibilities included:
The COVID-19 pandemic has pushed healthcare systems globally to a breaking point. The urgent need for effective and affordable COVID-19 treatments calls for repurposing combinations of approved drugs. The challenge is to identify which combinations are likely to be most effective and at what stages of the disease. Here, we present the first disease-stage executable signalling network model of SARS-CoV-2-host interactions used to predict effective repurposed drug combinations for treating early- and late stage severe disease. Using our executable model, we performed in silico screening of 9870 pairs of 140 potential targets and have identified nine new drug combinations. Camostat and Apilimod were predicted to be the most promising combination in effectively supressing viral replication in the early stages of severe disease and were validated experimentally in human Caco-2 cells. Our study further demonstrates the power of executable mechanistic modelling to enable rapid pre-clinical evaluation of combination therapies tailored to disease progression. It also presents a novel resource and expandable model system that can respond to further needs in the pandemic.
Cells with higher levels of Myc proliferate more rapidly and supercompetitively eliminate neighboring cells. Nonetheless, tumor cells in aggressive breast cancers typically exhibit significant and stable heterogeneity in their Myc levels, which correlates with refractoriness to therapy and poor prognosis. This suggests that Myc heterogeneity confers some selective advantage on breast tumor growth and progression. To investigate this, we created a traceable MMTV-Wnt1 –driven in vivo chimeric mammary tumor model comprising an admixture of low-Myc– and reversibly switchable high-Myc–expressing clones. We show that such tumors exhibit interclonal mutualism wherein cells with high-Myc expression facilitate tumor growth by promoting protumorigenic stroma yet concomitantly suppress Wnt expression, which renders them dependent for survival on paracrine Wnt provided by low-Myc–expressing clones. To identify any therapeutic vulnerabilities arising from such interdependency, we modeled Myc/Ras/p53/Wnt signaling cross talk as an executable network for low-Myc, for high-Myc clones, and for the 2 together. This executable mechanistic model replicated the observed interdependence of high-Myc and low-Myc clones and predicted a pharmacological vulnerability to coinhibition of COX2 and MEK. This was confirmed experimentally. Our study illustrates the power of executable models in elucidating mechanisms driving tumor heterogeneity and offers an innovative strategy for identifying combination therapies tailored to the oligoclonal landscape of heterogenous tumors.